	US 11,718,674 B2
	Antibodies binding PD-L1 and uses thereof
Jiangmei Li, Beijing (CN); Wenqi Hu, Beijing (CN); and Feng Li, Beijing (CN)
Assigned to BEIJING MABWORKS BIOTECH CO., LTD., Beijing (CN)
Filed by Beijing Mabworks Biotech Co. Ltd., Beijing (CN)
Filed on Aug. 30, 2021, as Appl. No. 17/460,560.
Claims priority of application No. 202110284404.8 (CN), filed on Mar. 16, 2021.
Prior Publication US 2022/0298244 A1, Sep. 22, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01)]

15 Claims

1. An isolated monoclonal antibody, or an antigen-binding portion thereof, binding to PD-L1, comprising a heavy chain variable region comprising a VH-CDR1 region, a VH-CDR2 region and a VH-CDR3 region, and a light chain variable region comprising a VL-CDR1 region, a VL-CDR2 region and a VL-CDR3 region, wherein the VH-CDR1 region, the VH-CDR2 region, the VH-CDR3 region, the VL-CDR1 region, the VL-CDR2 region and the VL-CDR3 region comprise amino acid sequences of (1) SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively; or (2) SEQ ID NOs: 7, 8, 9, 10, 11 and 12, respectively.